Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (5): 85-95.doi: 10.6040/j.issn.1673-3770.0.2022.459

• Original Article • Previous Articles     Next Articles

Expression of TGFBI in head and neck squamous cell carcinoma and its clinical significance

ZHOU Yijing, ZOU Jianyin, YI Hongliang, WU Hongmin   

  1. Department of Otolaryngology & Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
  • Published:2023-10-13

PDF (PC)

278

Abstract: Objective To explore the expression of transforming growth factor β induced gene(TGFBI)in head and neck squamous cell carcinoma(HNSCC)and its clinical significance. Methods Single-cell RNA-Seq sequencing data from the NCBI database were used to analyze TGFBI expression in immune cells and Bulk RNA-Seq was used to explore the infiltration of the tumor microenvironment in HNSCC. The gene expression and prognostic value of TGFBI in HNSCC were analyzed using TCGA database and validated using clinical specimens. TCGA database were used to assess the response of HNSCC patients to targeted therapy and immunotherapy after grouping according to TGFBI expression and to analyse the effect of gene mutations on TGFBI expression. Results High TGFBI was expressed in M2 macrophages. High TGFBI was associated with poor prognosis in patients with HNSCC. Patients with low TGFBI expression may respond to immunotherapy, while patients with high TGFBI expression may respond to targeted therapy. Mutations in TP53 were significantly associated with high TGFBI expression. Conclusion There is some evidence that TGFBI can be used as a biomarker for predicting survival and treatment response in patients with HNSCC.

Key words: Head and neck squamous cell carcinoma, Transforming growth factor β induced gene, Immune infiltration, Immunotherapy, Targeted therapy

CLC Number: 

  • R735.1
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. doi: 10.3322/caac.21654
[2] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021. doi:10.1002/ijc.33588
[3] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92. doi:10.1038/s41572-020-00224-3
[4] Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck[J]. Front Oncol, 2017, 7: 72. doi:10.3389/fonc.2017.00072
[5] Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11): 1116-1127. doi:10.1056/NEJMoa0802656
[6] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28. doi:10.1016/S1470-2045(09)70311-0
[7] 卫亚楠, 陈曦. 局部晚期头颈部鳞状细胞癌的化疗及靶向进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 118-124. doi:10.6040/j.issn.1673-3770.0.2020.276 WEI Yanan, CHEN Xi. Progress in chemotherapy and targeted drug therapy for locally advanced head and neck squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 118-124. doi:10.6040/j.issn.1673-3770.0.2020.276
[8] Steitz AM, Steffes A, Finkernagel F, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced(TGFBI)and tenascin C[J]. Cell Death Dis, 2020, 11(4): 249. doi:10.1038/s41419-020-2438-8
[9] Pajares MJ, Agorreta J, Salvo E, et al. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients[J]. Br J Cancer, 2014, 110(6): 1545-1551. doi:10.1038/bjc.2014.33
[10] Suzuki M, Yokobori T, Gombodorj N, et al. High stromal transforming growth factor β-induced expression is a novel marker of progression and poor prognosis in gastric cancer[J]. J Surg Oncol, 2018, 118(6): 966-974. doi:10.1002/jso.25217
[11] Patry M, Teinturier R, Goehrig D, et al. βig-h3 represses T-cell activation in type 1 diabetes[J]. Diabetes, 2015, 64(12): 4212-4219. doi:10.2337/db15-0638
[12] McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors[J]. Cell Syst, 2019, 8(4): 329-337.e4. doi:10.1016/j.cels.2019.03.003
[13] Kabutoya T, Ohmori T, Fujiwara T, et al. Combination therapy with an Xa inhibitor and antihypertensive agent improved anticoagulant activity in patients with nonvalvular atrial fibrillation: the hypertension and atrial fibrillation treated by rivaroxaban for the morning and night with sYnergy with calcium antagonists(HARMONY)study[J]. Clin Exp Hypertens, 2020, 42(4): 365-370. doi:10.1080/10641963.2019.1665678
[14] Cheng SJ, Li ZY, Gao RR, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells[J]. Cell, 2021, 184(3): 792-809.e23. doi:10.1016/j.cell.2021.01.010
[15] Tang ZF, Kang BX, Li CW, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): W556-W560. doi:10.1093/nar/gkz430
[16] Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data[J]. Methods Mol Biol, 2020, 2120: 223-232. doi:10.1007/978-1-0716-0327-7_16
[17] Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels[J]. PLoS One, 2014, 9(9): e107468. doi:10.1371/journal.pone.0107468
[18] Chen Y, Li ZY, Zhou GQ, et al. An immune-related gene prognostic index for head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2021, 27(1): 330-341. doi:10.1158/1078-0432.CCR-20-2166
[19] Du KP, Zou JW, Wang BY, et al. A metabolism-related gene prognostic index bridging metabolic signatures and antitumor immune cycling in head and neck squamous cell carcinoma[J]. Front Immunol, 2022, 13: 857934. doi:10.3389/fimmu.2022.857934
[20] Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018, 554(7693): 544-548. doi:10.1038/nature25501
[21] Lauss M, Donia M, Harbst K, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma[J]. Nat Commun, 2017, 8(1): 1738. doi:10.1038/s41467-017-01460-0
[22] Gide TN, Quek C, Menzies AM, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy[J]. Cancer Cell, 2019, 35(2): 238-255.e6. doi:10.1016/j.ccell.2019.01.003
[23] Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018, 24(9): 1449-1458. doi:10.1038/s41591-018-0101-z
[24] Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer[J]. Genome Res, 2018, 28(11): 1747-1756. doi:10.1101/gr.239244.118
[25] Lenze NR, Farquhar DR, Dorismond C, et al. Age and risk of recurrence in oral tongue squamous cell carcinoma: systematic review[J]. Head Neck, 2020, 42(12): 3755-3768. doi:10.1002/hed.26464
[26] 杨惠茹, 鲁海珍. 头颈部鳞状细胞癌免疫治疗预测指标及分子标志物的研究进展[J]. 中国肿瘤, 2022, 31(5): 387-393. doi:10.11735/j.issn.1004-0242.2022.05.A011 YANG Huiru, LU Haizhen. Advances on predictive indicators for prognosis of head and neck squamous cell carcinoma[J]. China Cancer, 2022, 31(5): 387-393. doi:10.11735/j.issn.1004-0242.2022.05.A011
[27] Yin WM, Yu XL, Kang XJ, et al. Remodeling tumor-associated macrophages and neovascularization overcomes EGFRT790M-associated drug resistance by PD-L1 nanobody-mediated codelivery[J]. Small, 2018, 14(47): e1802372. doi:10.1002/smll.201802372
[28] Chen YL, Zhang SY, Wang QZ, et al. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein[J]. J Hematol Oncol, 2017, 10(1): 36. doi:10.1186/s13045-017-0408-0
[29] Liu XL, Zhang CH, Wang XM, et al. Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer[J]. Endocr Relat Cancer, 2023, 30(3): e220221. doi:10.1530/ERC-22-0221
[30] Hlophe YN, Joubert AM. Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion[J]. J Cell Mol Med, 2022, 26(23): 5743-5754. doi:10.1111/jcmm.17571
[31] Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2020, 21(6): 341-352. doi:10.1038/s41580-020-0237-9
[32] Teng CL, Yu CT, Hwang WL, et al. Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells[J]. Ann Hematol, 2013, 92(3): 301-313. doi:10.1007/s00277-012-1627-7
[33] Halbach S, Hu ZH, Gretzmeier C, et al. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells[J]. Cell Commun Signal, 2016, 14: 6. doi:10.1186/s12964-016-0129-y
[34] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring[J]. Am J Hematol, 2022, 97(9): 1236-1256. doi:10.1002/ajh.26642
[35] van Wigcheren GF, de Haas N, Mulder TA, et al. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients[J]. Oncoimmunology, 2021, 10(1): 1935557. doi:10.1080/2162402X.2021.1935557
[36] Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers[J]. Mol Cancer Ther, 2017, 16(11): 2598-2608. doi:10.1158/1535-7163.MCT-17-0386
[37] Hayashi Y, Tsujii M, Kodama T, et al. p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth[J]. Carcinogenesis, 2016, 37(10): 972-984. doi:10.1093/carcin/bgw085
[38] Salmon H, Remark R, Gnjatic S, et al. Host tissue determinants of tumour immunity[J]. Nat Rev Cancer, 2019, 19(4): 215-227. doi:10.1038/s41568-019-0125-9
[1] LIU Jiahui, TIAN Ruxian, LI Yumei, SONG Xicheng. Construct of a cuproptosis-related lncRNA model to predict prognosis in head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 49-64.
[2] GU Min, LU Meiping. Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 106-111.
[3] PAN Linlin, WAN Jiaming, LI Yue, HE Long. Autophagy-related long noncoding RNA is a prognostic indicator for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 97-107.
[4] XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.
[5] ZHANG Ting, WANG Meilan, GAO Yingqin. Research progress of IL-35 in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 139-147.
[6] YANG Ming, LIU Xuexia, ZHANG Hua. Progress of m6A recognition protein IGF2BPs in head and neck cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 153-161.
[7] ZHANG Yunqiu, REN Xiumin, XU Ou, DONG Jinhui, WANG Jianxing. Research progress on omalizumab targeted therapy for chronic sinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 136-140.
[8] XIE Yulin, LEI Dapeng. Advances in the pathological study of artificial intelligence in the lymph node metastasis of head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(3): 124-129.
[9] SONG Fei, SONG Hao, LI Yumei, MOU Yakui, SONG Xicheng. Immunomodulatory roles of tumor-derived exosomes in the microenvironment of head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 92-100.
[10] TU Qiaoling, LI Yufeng, PENG Jun. Advances in anti-PD-L1/PD-1 therapy and non-coding RNA regulation in nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 135-141.
[11] YANG Yingling, GOU Haocheng, FENG Jun. Review of pyroptosis molecular mechanism and applications in head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 160-165.
[12] SUO Anqi, YANG Xinxin. Research progress on the relationship between mitochondrial autophagy and squamous cell carcinoma of the head and neck [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 111-117.
[13] AI Ziqin, LI Junzheng. Advances in immune vaccines for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(2): 143-150.
[14] WANG MeiOverview,LI ZhihaiGuidance. Laryngeal cancer stem cells: potential therapeutic targets for overcoming multidrug resistance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 120-128.
[15] PANG Chong, BIAN Sainan, ZHANG Bing, YIN Xu, LU Yingxia, YE Pengfei, WANG Zhan, ZHAO Jing, GAO Yan, GUAN Kai. Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 70-74.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd